Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-1: mevrometostat + enzalutamide versus enzalutamide or docetaxel in abiraterone-pretreated metastatic castration-resistant prostate cancer
CTR20243666Phase 3Active
- Sponsor
- Pfizer
- Start
- Nov 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of mevrometostat, enzalutamide, docetaxel in prostate cancer (PCa), sponsored by Pfizer. Started Nov 2024; status: active.
02
Drugs
mevrometostatenzalutamidedocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on CTR20243666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243666.